Recently, Chinese scientists have successfully created beating heart organoids using 3D bioprinting technology—a breakthrough that offers new hope for cardiac research and regenerative medicine. These organoids are composed of cardiomyocytes derived from human induced pluripotent stem cells (iPSCs). By precisely controlling the composition of bioinks and printing parameters, researchers engineered miniature heart tissues with three-dimensional structure and spontaneous rhythmic contractions. Not only do these organoids mimic certain structural features of a real human heart, but they also respond to pharmacological stimuli, providing an efficient and reproducible in vitro platform for modeling cardiovascular diseases, drug screening, and personalized therapy. Importantly, this approach avoids the ethical concerns associated with traditional animal testing and holds potential for future applications such as repairing damaged heart tissue or developing artificial hearts. The research team is now working to enhance the maturity and vascularization of these organoids to bring them closer to clinical use. This achievement marks a significant step forward for China in the fields of biomanufacturing and regenerative medicine, opening new avenues for global cardiac disease treatment.
近日，中国科学家成功利用3D生物打印技术制造出具有跳动功能的心脏类器官，这一突破为心脏病研究和再生医学带来了新的希望。该类器官由人类诱导多能干细胞（iPSCs）分化而来的心肌细胞构成，通过精确控制生物墨水的成分与打印参数，研究人员成功构建出具备三维结构和自发节律性收缩能力的微型心脏组织。这种心脏类器官不仅在形态上模拟真实心脏的部分结构，还能对药物刺激产生反应，为心血管疾病建模、药物筛选及个性化治疗提供了高效、可重复的体外平台。更重要的是，这项技术避免了传统动物实验的伦理争议，并有望在未来用于修复受损心肌或开发人工心脏。目前，研究团队正致力于提升类器官的成熟度与血管化水平，以进一步接近临床应用。这一成果标志着中国在生物制造和再生医学领域迈出了关键一步，也为全球心脏疾病治疗开辟了新路径。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/15812.html